Wockhardt’s Zaynich antibiotic gains CDSCO approval

Zaynich, a novel broad-spectrum antibiotic by Wockhardt, targets multi-drug resistant bacterial infections. Recommended dosing follows label guidelines; approved by CDSCO on 27 May ahead of anticipated FDA approval, with EMA filing underway. Now available in India, it offers dentists a new option for managing resistant oral and maxillofacial infections.